Drug Trial Radar · NCT06030193
Study of an Investigational Product, QLS-111, Provided as an Eyedrop, for Treatment of Normal Tension Glaucoma (NTG)
Last checked: Nov 19, 2026Latest source record: Apr 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
37
Actual
Start
Aug 13, 2025
Primary completion
Feb 23, 2026
Study completion Mar 23, 2026
Sponsor
- Lead sponsor
- Qlaris Bio, Inc.Industry
- Sponsor type
- Industry
- First posted
- Sep 8, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 30 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Qlaris' Phase 2 clinical trial investigating the safety, tolerability, and ocular hypotensive efficacy of QLS-111 in normal tension glaucoma patients.
Conditions
- Normal Tension Glaucoma (NTG)
- Low-Tension Glaucoma, Bilateral
- Low-Tension Glaucoma, Unspecified Eye
- Glaucoma
Interventions
QLS-111 ophthalmic solution (0.015%)Drug
QLS-111 ophthalmic solution 0.015% applied QPM OU for 7 days followed by BID dosing OU for 7 days, to constitute a 14-day study treatment period. All IP for this study will be supplied masked in PF single use vials.
Timolol Maleate PF 0.5% Ophthalmic Solution (Timolol)Drug
Timolol BID: Timolol Maleate PF 0.5% Ophthalmic Solution (Timolol) with BID dosing OU will be administered up to 14 days. All IP for this study will be supplied masked in PF single use vials.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of ocular symptoms and ocular treatment-emergent adverse events (TEAEs)Time frame: 14 days
- Clinically significant change in visual acuityTime frame: 14 days
- Clinically significant change in findings on slit lamp examTime frame: 14 days
- Clinically significant change in findings on fundus examTime frame: 14 days
- Incidence of systemic TEAEsTime frame: 14 days
- Clinically significant changes in blood pressure (BP)Time frame: 14 days
- Clinically significant changes in heart rate (HR)Time frame: 14 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Seoul National University Hospital
Seoul, South Korea
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.